Laviana Pharma Completed Nearly 100 Million Yuan B+ Round Financing, To Provide CDMO Services for Small Molecule Innovative Drugs

According to 36Kr, Laviana Pharma, which focuses on small molecule innovative drugs, has received B+ round financing of nearly 100 million yuan, led by V-Capital and invested by CMW Asset Management. This round of financing will be mainly used for research and development of technology, and construction of the operation team.

Found in 2005，Laviana Pharma is a high-tech enterprise. It specializes in providing processes and manufactures outsourcing services (CDMO) for the pharmaceutical industry. The main scope of services covers all chemistry-related aspects of process development and transformation for products including process research, process development, process optimization, pilot production, and large-scale production. 

Laviana Pharma also provides CMC services for IND and NDA submission of the innovative developmental drugs. It has three wholly-owned subsidiaries, namely, Beijing Laviana Pharmatech Co., Ltd., Laviana (Tianjin) Pharmatech Development Co., Ltd., and Laviana Corporation incorporated in the United States. 

So far, Laviana Pharma has formed an open technology platform, covering technological transformation from the laboratory to the factory of innovation medicine (mainly small molecule drugs). The platform is involved in the treatment of antiviral, anti-tumor, cardiovascular and metabolic system diseases, and central nervous system diseases, etc.

V-Capital is supporting Chinese enterprises with transformation and upgrading by M&A or other strategic cooperative methods, sculpturing the art of investment globally.

They invest globally based on the demands of our clients. We also deliver strategic advice and solutions to Chinese public corporations, private enterprises, and other institutions.

CMW Asset Management is a provider of financial management, wealth products, alternative investments, equity investment, and other related services.